FDA Inspection Report Cites Theranos Used “Uncleared Medical Device” | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

FDA Inspection Report Cites Theranos Used “Uncleared Medical Device”

October 27, 2015
by Heather Landi
| Reprints

The U.S. Food and Drug Administration found flaws in the process that medical testing company Theranos used to validate its blood-testing products, according to inspections reports the agency posted to its website.

The FDA has posted two inspection reports to its website based on inspections conducted August 25th through September 16th at Theranos’ Palo Alto, Calif. and Newark, N.J. facilities.

Healthcare Informatics obtained access to the FDA inspection reports from a link in an online article posted by Bloomberg Business.

Theranos is a biomedical startup that has developed technology for a blood testing device that requires only a finger prick blood sample for lab tests, as opposed to patients’ getting their blood drawn via a needle in a doctor’s office or lab, which often requires vials of blood.

One inspection report, which is heavily redacted, states that the “design validation did not ensure the device conforms to defined user needs and intended uses” and that the “design was not validated under actual or simulated use conditions.”

In a second inspection report for Theranos, Inc., the FDA states that the company’s “capillary tube nanotainer (CTN), a blood specimen collection device,” which refers to the small vials the company uses for the finger stick blood sample, is a “Class II medical device,” yet Theranos listed the device as a “Class I exempt medical device.”

The inspection report states, “You are currently shipping this uncleared medical device in interstate commerce, between California, Arizona and Pennsylvania.”

According to the Bloomberg Business article, the company said it had “addressed and corrected all the observations at the time of, or within a week of, the inspection.”

While Theranos lists about 200 tests on its online menu, the company said this month that it is using its new technology on only one test.

Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More

Topics

News

Study will Leverage Connecticut HIE to Help Prevent Suicides

A new study will aim to leverage CTHealthLink, a physician-led health information exchange (HIE) in Connecticut, to help identify the factors leading to suicide and to ultimately help prevent those deaths.

Duke Health First to Achieve HIMSS Stage 7 Rating in Analytics

North Carolina-based Duke Health has become the first U.S. healthcare institution to be awarded the highest honor for analytic capabilities by HIMSS Analytics.

NIH Releases First Dataset from Adolescent Brain Development Study

The National Institutes of Health (NIH) announced the release of the first dataset from the Adolescent Brain Cognitive Development (ABCD) study, which will enable scientists to conduct research on the many factors that influence brain, cognitive, social, and emotional development.

Boston Children's Accelerates Data-Driven Approach to Clinical Research

In an effort to bring a more data-driven approach to clinical research, Boston Children’s Hospital has joined the TriNetX global health research network.

Paper Records, Films Most Common Type of Healthcare Data Breach, Study Finds

Despite the high level of hospital adoption of electronic health records and federal incentives to do so, paper and films were the most frequent location of breached data in hospitals, according to a recent study.

AHA Appoints Senior Advisor for Cybersecurity and Risk

The American Hospital Association (AHA) has announced that John Riggi has joined the association as senior advisor for cybersecurity and risk.